The purpose of this registry is to assess clinical outcomes, and different factors that may affect these clinical outcomes such as systems of care, associated with the use of Covidien market-released neurothrombectomy devices intended to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion.
This is a prospective, multi-center, non-randomized, observational registry of acute ischemic stroke patients that have or will undergo treatment with the use of a Covidien market-released neurothrombectomy device (as the initial device used to remove the thrombus) within 8 hours of stroke symptom onset, at the discretion of the investigator and independent of participation in this registry. This registry may enroll up to 1000 patients.
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Acute Ischemic Stroke Patients
|Type||Measure||Time Frame||Safety Issue|
|Primary||Status of revascularization at the end of the interventional procedure||Day 0||No|
|Secondary||Symptomatic intracranial hemorrhage||1 day||No|
|Secondary||Incidence of Neurological Events of Interest||up to 90 days post index procedure|